An immuno-oncology company developing targeted and effective immunotherapies for advanced breast cancer and other cancers. (Nasdaq: $BCTX, $BCTXL) (TSX: BCT)
We’re Hiring at Briacell Therapeutics!
BriaCell is on a mission to transform cancer therapy, and we need talented individuals who are excited to help shape the future of biotech. Come work alongside a dedicated team where your ideas and impact truly matter.
See our open roles here: https://t.co/BL0lWSRJja
BriaCell President and CEO Dr. William V. Williams highlights positive preclinical findings from four research posters presented by BriaCell and BriaPro at the #SITC2026 Annual Meeting, November 4–8, in Phoenix, AZ. Learn more: https://t.co/u7TJVVymkU $BCTX $BCTXL
BriaCell and BriaPro today announced preclinical findings from four posters at the Society for Immunotherapy of Cancer (#SITC26) 41th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.
The presentations highlight BriaCell’s Bria-OTS+ off-the-shelf cellular immunotherapy platform and BriaPro’s BP-80 and TILsRx #immunotherapy programs, including advances in engineered CD80 proteins. For highlights of the SITC 2026 presentations, visit: https://t.co/x6pYZtNBgX $BCTX $BCTXL
“We are honored to receive this recognition from BioTech Breakthrough. BriaCell is committed to helping patients facing late-stage metastatic breast cancer,” said Dr. William V. Williams, President & CEO of BriaCell. Learn more about the @TopTechAwards: https://t.co/tItUSbLtRQ $BCTX $BCTXL
“The four presentations provide additional preclinical data supporting our cellular and protein-based immunotherapy research,” said BriaCell President and CEO Dr. William V. Williams. The presentations will highlight the company's Bria-OTS+ cellular #immunotherapy platform and BriaPro's CD80-based immunotherapy programs at #SITC2026, November 4–8, in Phoenix, AZ. Learn more: https://t.co/vxf2CGPtcw $BCTX $BCTXL
BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, announced today that it has awarded BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) for “Immunotherapy Solution of the Year” in its sixth annual @TopTechAwards. Read the full press release for more information: https://t.co/tItUSbLtRQ $BCTX $BCTXL
BriaCell Chief Scientific Officer Dr. Miguel A. Lopez-Lago highlights new preclinical findings supporting continued investigation of the Bria-OTS+ cellular #immunotherapy platform. The findings will be presented at #SITC2026, November 4–8, in Phoenix, AZ. Find more information: https://t.co/vxf2CGPtcw $BCTX $BCTXL
Join the BriaCell Team!
Briacell Therapeutics is expanding, and we're looking for enthusiastic, driven professionals ready to make a difference in cancer treatment. If you're passionate about biotech innovation and thrive in a collaborative environment, we want to hear from you!
Explore our current opportunities here: https://t.co/BL0lWSRJja
BriaCell and BriaPro announced four preclinical research presentations at the Society for Immunotherapy of Cancer (#SITC26) 41th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.
The presentations cover BriaCell’s personalized off-the-shelf #immunotherapy platform, Bria-OTS+™, and three BriaPro research programs: BP-80, a soluble CD80-Fc fusion protein; TILsRx-001, a tumor-targeted CD80-based checkpoint inhibitor; and engineered CD80 variants with altered immune receptor binding. Find details: https://t.co/vxf2CGPtcw $BCTX $BCTXL
BriaCell CEO Dr. Williams recently spoke with @pulse2news about the company’s approach to cancer #immunotherapy, the potential of its off-the-shelf cellular platform, and the future of its clinical pipeline.
The interview explores how BriaCell’s approach aims to combine the precision of personalized medicine with the accessibility of off-the-shelf therapies, including its lead candidate, Bria-IMT, currently being evaluated in a pivotal Phase 3 trial for #metastaticbreastcancer. Read the full interview: https://t.co/mzX0JOD8pu $BCTX $BCTXL
BriaCell is hiring!
Briacell Therapeutics is expanding our team and looking for passionate, driven individuals to join us in advancing innovative cancer treatments. If you're ready to make a meaningful impact in biotech and work alongside a dedicated team, we'd love to hear from you.
Explore our open roles and take the next step in your career today. https://t.co/BL0lWSRJja
A new @AJMC_Journal article highlights BriaCell’s Bria-IMT™ as an off-the-shelf #immunotherapy being evaluated for patients with #metastaticbreastcancer following treatment with antibody-drug conjugates (ADCs).
The article highlights the ongoing pivotal Phase 3 Bria-ABC study, final Phase 2 data showing a median overall survival of 16.6 months, and recent biomarker findings presented at #ESMO26.
Read the full article: https://t.co/ZE1cxI73G3 $BCTX $BCTXL
BriaCell��s Chief Medical Officer, Dr. Giuseppe Del Priore, highlights findings presented at the #ESMO26 Congress supporting further evaluation of circulating CAML PD-L1 as a potential biomarker of clinical benefit in #metastaticbreastcancer. Learn more: https://t.co/A56QwXaGgz $BCTX $BCTXL
BriaCell will present new clinical biomarker findings at the #ESMO26 Congress highlighting CAML PD-L1 as a potential biomarker of clinical outcomes in #metastaticbreastcancer.
“We are encouraged by these findings showing that dynamic changes in a circulating immune biomarker were associated with progression-free and overall survival in patients with metastatic breast cancer treated with immunotherapies,” stated Dr. William V. Williams, BriaCell’s President and CEO. For more: https://t.co/A56QwXaGgz $BCTX $BCTXL
BriaCell announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients with #metastaticbreastcancer treated with immune based therapies including the BriaCell regimen at the #ESMO26 Congress, taking place October 23-27, 2026 in Madrid, Spain.
The data shown is pooled from several studies including BriaCell’s Phase 1/2 Bria-IMT study. For additional presentation information: https://t.co/A56QwXaGgz $BCTX $BCTXL
BriaCell CEO Dr. William V. Williams recently joined The Bio Report, hosted by Daniel Levine, to discuss the development of BriaCell’s off-the-shelf, cell-based #immunotherapies for #metastaticbreastcancer. Listen to the full interview: https://t.co/ZE1cxI73G3 $BCTX $BCTXL #TheBioReport
BriaCell is featured in a recent @PrismMarketView article, “Closing the Gap: Emerging Biotechs Take Aim at Metastatic Breast Cancer.”
The article highlights the continued unmet need in #metastaticbreastcancer and BriaCell’s pivotal Phase 3 Bria-ABC study evaluating Bria-IMT in combination with a checkpoint inhibitor.
Read the full article: https://t.co/ZE1cxI73G3
$BCTX $BCTXL
Join us in recognizing Men's #BreastCancerAwareness Week, October 17-23.
While #breastcancer is more common in women, it can also affect men. This week, we're highlighting the importance of awareness, education and research for everyone impacted by #breastcancer. Learn more: https://t.co/IIJ0bjzLgX
#BCAM #noveltherapies #cancertherapies #MBC
BriaCell CEO Dr. William V. Williams joins Johny Fernandez of @fintechtvglobal to discuss the company’s pivotal Phase 3 trial of Bria-IMT and the progress toward its headline data readout.
Dr. Williams also highlights Bria-OTS, BriaCell’s off-the-shelf immunotherapy approach designed to match more than 99% of patients, and encouraging clinical results observed in metastatic breast cancer.
Watch the full interview: https://t.co/ZE1cxI73G3
$BCTX $BCTXL